Drug abuse involving opiates, cannabinoids, and amphetamines has been growing globally, creating a public health crisis that requires immediate and scalable solutions. Healthcare providers, law enforcement agencies, and employers are increasingly relying on POC drug testing as it offers rapid, accurate, and on-site detection, which is critical in managing the consequences of drug abuse.
In healthcare, the need for quick detection of drug abuse is essential to offer timely interventions, especially in emergency cases or rehabilitation centers. In law enforcement, the ability to test individuals on-site accelerates decision-making and enhances efforts to curb drug-related crimes. Similarly, workplaces are adopting POC drug testing to maintain a drug-free environment, reduce liability, and comply with safety regulations.
Technological advancements in POC testing devices further support the growing demand for rapid, reliable testing methods. These devices are becoming more portable, user-friendly, and capable of detecting a wide range of substances, making them ideal for use in non-laboratory settings.
The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.
Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.
Increased awareness of substance abuse and the easy availability of these kits through pharmacies and online platforms are contributing to market growth. The trend is further supported by a growing preference for non-invasive sample collection methods, such as saliva or urine tests, which are simple to use at home.
Access Full Report @ https://www.databridgemarketresearch.com/zh/reports/global-point-of-care-poc-drug-abuse-testing-market
Data Bridge Market Research analyzes that the Point-of-Care (POC) Drug Abuse Testing Market is expected to grow at a CAGR of 4.7% in the forecast period of 2024 to 2031 and is expected to reach USD 2.01 billion by 2031 from USD 1.41 billion in 2023, amphetamines segment is projected to propel the market growth due to its vast properties and have more demand among the population.
Key Findings of the Study
- Growth in Home and Parental Drug Testing Kits
The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.
Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.
Increased awareness of substance abuse and the easy availability of these kits through pharmacies and online platforms are contributing to market growth. The trend is further supported by a growing preference for non-invasive sample collection methods, such as saliva or urine tests, which are simple to use at home.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Norway, Austria, Hungary, Ireland, Kazakhstan, Belarus, Lithuania, Uzbekistan, Azerbaijan, Armenia, Moldova, Tajikistan, Kyrgyzstan, Poland, Rest of Europe, Brazil, Argentina, Colombia, Peru, Chile, EI Salvador, Panama, Bolivia, Costa Rica, Ecuador, Guatemala, Paraguay, Venezuela, Dominican Republic, Cuba, Uruguay, Rest of Latin America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Kuwait, and Rest of Middle East and Africa, China, India, Japan, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Abbott Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), MP Biomedicals (U.S.), Beijing Hotgen Biotech Co., Ltd. (China), Assure Tech (Hangzhou) Co., Ltd. (China), Accubio Tech Co., Ltd. (China), Premier Biotech, Inc. (U.S.), Wondfo (China) and, among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand
|
Segment Analysis
The global Point-of-Care (POC) drug abuse testing market is segmented into eight notable segments based on drug type, products, prescription, sample type, testing type, application, end user, and distribution channel.
- Based on drug type, the market is segmented into amphetamines, cannabinoids, opiates, cocaine, benzodiazepines, barbiturates, phencyclidine, methadone, tricyclic antidepressants, and others
In 2024, the amphetamine segment is expected to dominate the global Point-of-Care (POC) drug abuse testing market
In 2024, the amphetamines segment is expected to dominate the market with a market share of 22.98% due to its vast properties and have more demand among the population.
- Based on products, the market is segmented into devices, consumables and accessories
In 2024, the devices segment is expected to dominate the global Point-of-Care (POC) drug abuse testing market
In 2024, the devices segment is expected to dominate the market with a market share of 65.06% due to its convenience and continuous monitoring capabilities, allowing it to detect the drugs.
- Based on prescription, the market is segmented into prescription-based testing and over the counter testing. In 2024, the over the counter testing segment is expected to dominate the market with a market share of 59.99%
- Based on sample type, the market is segmented into urine, saliva, blood, hair, breath, and others. In 2024, the urine segment is expected to dominate the market with a market share of 27.97%
- Based on testing type, the market is segmented into random testing, post-incident testing and abstinence testing. In 2024, the random testing segment is expected to dominate the market with a market share of 45.22%
- Based on application, the market is segmented into medical screening, workplace screening, law enforcement and criminal justice, pain management, substance abuse treatment and rehabilitation, parental or home drug testing, sports and athletics testing, drug screening in schools and educational institutions, and others. In 2024, the medical screening segment is expected to dominate the market with a market share of 32.43%
- Based on end user, the market is segmented into healthcare facilities, employers, government institutes, and others. In 2024, the healthcare facilities segment is expected to dominate the market with a market share of 44.27%
- Based on distribution channel, the market is segmented into direct tender, retail sales and others. In 2024, the direct sales segment is expected to dominate the market with a market share of 60.89%
Major Players
Data Bridge Market Research analyzes Abbott Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Siemens Healthineers AG (Germany) as the major players operating on the market.
Market Development
- In August 2024, Abbott announced a global partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed
- In March 2024, Abbott extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-2027 season, continuing as their Global Health Sciences and Nutrition Partner. Since 2021, Abbott provided over 25,000 hours of nutrition education and screened more than 3,000 children for malnutrition
- In August 2023, SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities. The partnership with SSM Health benefits Siemens Healthineers by expanding its market presence, increasing visibility of its technology, fostering long-term growth, and enhancing its reputation in the healthcare sector
- In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
- In November 2023, Roche launched next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges. Roche’s next-generation qPCR system boosts its market position, meets clinical and public health needs, and opens new revenue opportunities while showcasing its commitment to innovation
Country Analysis
Geographically, the countries covered in the global Point-of-Care (POC) drug abuse testing market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Norway, Austria, Hungary, Ireland, Kazakhstan, Belarus, Lithuania, Uzbekistan, Azerbaijan, Armenia, Moldova, Tajikistan, Kyrgyzstan, Poland, rest of Europe, Brazil, Argentina, Colombia, Peru, Chile, EI Salvador, Panama, Bolivia, Costa Rica, Ecuador, Guatemala, Paraguay, Venezuela, Dominican Republic, Cuba, Uruguay, Rest of Latin America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Kuwait, and rest of Middle East and Africa, China, India, Japan, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and rest of Asia-Pacific.
As per Data Bridge Market Research analysis:
North America is expected to dominate the global Point-of-Care (POC) drug abuse testing market
North America is expected to dominate the global Point-of-Care (POC) drug abuse testing market owing to the rising healthcare expenditure.
Asia-Pacific is expected to be the fastest growing region in the global Point-of-Care (POC) drug abuse testing market
Asia-Pacific is expected to be the fastest growing country because of its growing healthcare infrastructure.
For more detailed information about the global Point-of-Care (POC) drug abuse testing market, click here – https://www.databridgemarketresearch.com/zh/reports/global-point-of-care-poc-drug-abuse-testing-market
